Will targeting B cells be the answer for Sjögren's syndrome?
Looney
R John
RJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000502:physiology; D016175:B-Lymphocyte Subsets / Q000473:pathology; D001402:B-Lymphocytes / Q000473:pathology*; D006801:Humans; D008212:Lymphocyte Depletion / Q000379:methods; D000069283:Rituximab; D012793:Sialadenitis / Q000209:etiology / Q000473:pathology; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D053264:B-Cell Activating Factor; C505719:TNFSF13B protein, human; D000069283:Rituximab